How Praluent Lowers Cholesterol
Praluent (alirocumab) is a monoclonal antibody that targets PCSK9, a protein produced mainly by the liver. PCSK9 binds to LDL receptors on liver cells, marking them for destruction and reducing the liver's ability to clear low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol) from the blood. By binding to PCSK9 and preventing this interaction, Praluent allows more LDL receptors to stay on liver cell surfaces. These receptors then capture and remove more LDL-C from circulation, lowering blood cholesterol levels.[1][2]
Patients typically receive Praluent as a subcutaneous injection every two weeks or monthly, with effects visible within weeks and sustained LDL-C reductions of 50-60% in clinical trials when added to statins.[3]
How Does PCSK9 Mechanism Differ from Statins?
Statins block HMG-CoA reductase, an enzyme in cholesterol synthesis, indirectly upregulating LDL receptors. Praluent directly blocks PCSK9 to boost receptor recycling, offering additive LDL-C lowering (up to 60% more) for statin-intolerant patients or those not reaching targets. This makes it suitable for high-risk cardiovascular patients with familial hypercholesterolemia or atherosclerotic disease.[1][4]
What Happens in Patients with Genetic PCSK9 Mutations?
People with natural PCSK9 loss-of-function mutations have lifelong low LDL-C (as low as 15-30 mg/dL) and reduced heart disease risk, mimicking Praluent's effect. Clinical data confirm Praluent replicates this by sustaining receptor levels, with no major impact on HDL or triglycerides.[2][5]
Common Side Effects and Injection Reactions
Most patients tolerate Praluent well, but 5-10% report injection-site reactions like redness or itching. Rare risks include allergic responses or muscle pain, though less common than with statins. Long-term studies show no increased neurocognitive effects despite LDL-C drops below 25 mg/dL.[3][6]
Who Makes Praluent and When Do Patents Expire?
Sanofi and Regeneron developed Praluent. Key U.S. patents cover the PCSK9 antibody sequence and formulations, with some expiring around 2030-2034; challenges from Amgen and others have narrowed claims. Check DrugPatentWatch.com for latest expiry dates and generic entry timelines.[7]
Sources
[1] FDA Label for Praluent
[2] NEJM: PCSK9 Inhibition Mechanism
[3] ODYSSEY Trials Summary
[4] ESC Guidelines on Dyslipidemia
[5] Nature Genetics: PCSK9 Mutations
[6] Praluent Safety Data
[7] DrugPatentWatch: Praluent Patents